Search Results - "Camacho, L H"

A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors by Pant, S., Saleh, M., Bendell, J., Infante, J.R., Jones, S., Kurkjian, C.D., Moore, K.M., Kazakin, J., Abbadessa, G., Wang, Y., Chen, Y., Schwartz, B., Camacho, L.H.

“…Tivantinib (ARQ 197) is an orally available, non-adenosine triphosphate competitive, selective c-MET inhibitor. The primary objective of this study was to…”
Get full text

A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis by Santoro, A, Simonelli, M, Rodriguez-Lope, C, Zucali, P, Camacho, L H, Granito, A, Senzer, N, Rimassa, L, Abbadessa, G, Schwartz, B, Lamar, M, Savage, R E, Bruix, J

“…Background: The mesenchymal-epithelial transition factor (MET) receptor is dysregulated in hepatocellular carcinoma (HCC), and tivantinib (ARQ 197) is an oral,…”
Get full text

Phase II trial of imatinib mesylate in patients with metastatic melanoma by Kim, K B, Eton, O, Davis, D W, Frazier, M L, McConkey, D J, Diwan, A H, Papadopoulos, N E, Bedikian, A Y, Camacho, L H, Ross, M I, Cormier, J N, Gershenwald, J E, Lee, J E, Mansfield, P F, Billings, L A, Ng, C S, Charnsangavej, C, Bar-Eli, M, Johnson, M M, Murgo, A J, Prieto, V G

“…Metastatic melanoma cells express a number of protein tyrosine kinases (PTKs) that are considered to be targets for imatinib. We conducted a phase II trial of…”
Get full text

Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome by MASLAK, P, CHANEL, S, CAMACHO, L. H, SOIGNET, S, PANDOLFI, P. P, GUERNAH, I, WARRELL, R, NIMER, S

“…Epigenetic mechanisms underlying tumorigenesis have recently received much attention as potential therapeutic targets of human cancer. We designed a pilot…”
Get full text

Phase I study of the effects of renal impairment on the pharmacokinetics and safety of satraplatin in patients with refractory solid tumors by Galsky, M.D., Camacho, L.H., Chiorean, E.G., Mulkerin, D., Hong, D.S., Oh, W.K., Bajorin, D.F.

“…Satraplatin is an oral platinum analog with demonstrated activity in a range of malignancies. The current study was designed to evaluate the effect of varying…”
Get full text

Leukocytosis and the Retinoic Acid Syndrome in Patients With Acute Promyelocytic Leukemia Treated With Arsenic Trioxide by CAMACHO, L. H, SOIGNET, S. L, CHANEL, S, HO, R, HELLER, G, SCHEINBERG, D. A, ELLISON, R, WARRELL, R. P

“…Arsenic trioxide, like all-trans-retinoic acid (RA), induces differentiation of acute promyelocytic leukemia (APL) cells in vivo. Treatment of APL patients…”
Get full text

The eosinophilic response and haematological recovery after treatment for Plasmodium falciparum malaria by Camacho, Luis H., Wilairatana, Polarat, Weiss, Günter, Mercader, Marco A., Brittenham, Gary M., Looareesuwan, Sornchai, Gordeuk, Victor R.

“…SummaryTo examine a possible relationship between the immune response and haematological recovery after acute falciparum malaria, we followed peripheral blood…”
Get full text

Clinical applications of retinoids in cancer medicine by Camacho, L H

“…The retinoids are compounds structurally related to vitamin A. The most extensively studied agents in cancer medicine include all-trans-retinoic acid,…”
Get more information

The course of anaemia after the treatment of acute, falciparum malaria by Camacho, L. H., Gordeuk, V. R., Wilairatana, P., Pootrakul, P., Brittenham, G. M., Looareesuwan, S.

“…To determine the course of anaemia following treatment for acute falciparum malaria, 72 adult Thai patients were followed for 4 weeks after starting effective…”
Get full text

Expanding the genetic potential of the soybean by Camacho, L.H

“…The primary center of genetic dispersion of the soybean probably is in northeastern China. The soybean plant traveled from its area of origin to Korea and…”
Get full text

Phase Ib results of c-MET inhibitor ARQ 197 in combination with gemcitabine in a cohort of patients (pts) with advanced breast, ovarian, and uterine tumors by Camacho, L. H., Pant, S., Saleh, M. N., Abbadessa, G., Kazakin, J., Schwartz, B. E., Bendell, J. C.

“…Abstract only…”
Get full text

A phase I study of palifosfamide in combination with doxorubicin: Safety and preliminary efficacy by Camacho, L. H., Chawla, S. P., Chua, V., Abbadessa, G., Komarnitsky, P. B., Lewis, J.

“…Abstract only 10577 Background: Palifosfamide, a bi-functional DNA alkylator is the active metabolite of ifosfamide (IFOS), that lacks the toxicity associated…”
Get full text

Dual inhibition of VEGF pathway: Phase I trial of bevacizumab and cediranib in advanced solid tumors by Garrido-Laguna, I., Kurzrock, R., Wheler, J. J., Falchook, G. S., Piha-Paul, S. A., Fu, S., Naing, A., Hinojosa, C., Mistry, R., Scamardo, A., Culotta, K. S., Ekmekcioglu, S., Wen, S., Camacho, L. H., Ivy, S. P., Hong, D. S.

“…Abstract only…”
Get full text

Final results from ARQ 197-114: A phase Ib safety trial evaluating ARQ 197 in cirrhotic patients (pts) with hepatocellular carcinoma (HCC) by Zucali, P., Santoro, A., Rodriguez-Lope, C., Simonelli, M., Camacho, L. H., Senzer, N. N., Bolondi, L., Lamar, M., Abbadessa, G., Schwartz, B. E.

“…Abstract only…”
Get full text

Phase Ib dose-escalation trial evaluating c-MET inhibitor ARQ 197 administered in combination with gemcitabine to patients (pts) with advanced solid tumors by Camacho, L. H., Bendell, J. C., John-Reid, L., Campos, L. T., Jones, S. F., Kazakin, J., Savage, R., Schwartz, B. E., Abbadessa, G., Saleh, M. N.

“…Abstract only…”
Get full text

Evaluation of indibulin, a novel tubulin targeting-agent, in combination with capecitabine, with mathematically optimized dose scheduling by Lewis, J. J., Galsky, M. D., Camacho, L. H., Loesch, D. M., Komarnitsky, P. B., Norton, L.

“…Abstract only 2538 Background: Indibulin (IDB) is a novel, orally available tubulin-targeting molecule that perturbs cancer cell migration and mitosis. It is…”
Get full text

Antitumor Activity in Melanoma and Anti-Self Responses in a Phase I Trial With the Anti-Cytotoxic T Lymphocyte–Associated Antigen 4 Monoclonal Antibody CP-675,206 by RIBAS, Antoni, CAMACHO, Luis H, SHARMA, Amarnath, GLASPY, John A, GOMEZ-NAVARRO, Jesus, LOPEZ-BERESTEIN, Gabriel, PAVLOV, Dmitri, BULANHAGUI, Cecile A, MILLHAM, Robert, COMIN-ANDUIX, Begona, REUBEN, James M, SEJA, Elisabeth, PARKER, Charla A

“…Cytotoxic T lymphocyte-associated antigen 4 (CTLA4) blockade with CP-675,206, a fully human anti-CTLA4 monoclonal antibody, may break peripheral immunologic…”
Get full text

A phase I dose-escalation study of the safety and pharmacokinetics (PK) of XL184, a VEGFR and MET kinase inhibitor, administered orally to patients (pts) with advanced malignancies by Salgia, R., Hong, D. S., Camacho, L. H., Ng, C. S., Janisch, L., Ratain, M. J., Kurzrock, R.

“…Abstract only 14031 Background: XL184 is a potent orally available small molecule inhibitor of MET and VEGFR2/KDR, and also inhibits KIT, RET, FLT3, and Tie-2…”
Get full text

Combination of 5-azacytidine (5-AZA) and valproic acid (VPA) in advanced solid cancers: A phase I study by Soriano, A. O., Braiteh, F., Garcia-Manero, G., Camacho, L. H., Hong, D., Moulder, S., Ng, C., Kurzrock, R.

“…Abstract only 3547 Background: 5-AZA is a DNA hypomethylating agent. VPA is a histone deacetylase inhibitor (HDACI). The combination of hypomethylating agents…”
Get full text

Prognostic role of prior cytokine immunotherapy in outcome of treatment with tremelimumab (CP-675,206) in patients with metastatic melanoma by Bulanhagui, C. A., Gomez-Navarro, J., Antonia, S., Sosman, J. A., Kirkwood, J. M., Redman, B. G., Gajewski, T. F., Ribas, A., Camacho, L. H., Pavlov, D.

“…Abstract only…”
Get full text